Resources

In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 3 of this Exclusive Interview, Dr. Jim McDermott explains the DURATION-8 study of Bydureon and dapagliflozin combo therapy in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 4 of this Exclusive Interview, Dr. Jim McDermott discusses patient response to the DURATION-8 study, and the continuation of the study in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 5 of this Exclusive Interview, Dr. Jim McDermott explains DapaCare, the umbrella term that covers AstraZeneca's clinical program with Farxiga (dapagliflozin) in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 6, the conclusion of this Exclusive Interview, Dr. Jim McDermott explains SGLT2 cardiovascular trials, including the DECLARE trial that will complete in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

I recently met a patient whose life is alternative medicine. Not complementary medicine but alternative medicine. A young woman in her early 30’s who was diagnosed with type 1 diabetes 10 years ago. Besides having an A1C of 10.5%, I could tell she was struggling. Her career is in alternative medicine. For years she has been looking for a way to stop taking insulin. She is looking for the cure, but as with many, has difficulty believing it’s not here yet. She has had diabetes education, but because she hasn’t really met the hcp she can relate to or who has given her the answer she wants to hear, she’s not really put things together yet.

In this week's Homerun Slides, practical implementation of the common origins of diabetes and its complications construct.

OSA pathophysiology: OSA is a very complex disorder, and although obesity and fat deposition around the neck plays an important role, there are many other important players that contribute to the development of this condition. The human upper airway is a unique multipurpose structure involved in performing a variety of tasks such as speech, swallowing, and the passage of air for breathing. The airway, therefore, is composed of numerous muscles and soft tissue but lacks rigid or bony support. Most notably, it contains a collapsible portion that extends from the hard palate to the larynx, which allows the upper airway to change shape and momentarily for speech and swallowing during wakefulness; but this feature also provides the opportunity for collapse at inopportune times such as during sleep.

Meta-analysis explores safety and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type 1 diabetes.

Females with breast cancer and diabetes have poorer prognosis than those with breast cancer without diabetes, but why?